“Our Veltis technology platform offers multiple drug enhancement modalities for the development of more effective, safer and convenient therapeutics,” Jonas Skjodt Moller, COO of Albumedix, told us.
The platform, based on Albumedix’s engineered human albumin variant, has attracted interest by pharma and biotech companies looking to further enhance drug candidates, said Moller.
He continued, “Among other functional attributes this includes its validated capability to significantly prolong the duration of action of associated compounds.”
The agreement with Novartis covers the use of Albumedix technology across a range of molecules, targets, and mechanisms. Novartis could not comment further.
“We are very excited to be working with likeminded researchers at Novartis and see this as yet another step towards unlocking the full potential of albumin,” Moller said.
